Get the Stockscreener App
3.155
3.53%
-0.105
Overview
News
Price History
Option Chain
Financials
Why SAVA Down?
Discussions
Forecast
Stock Split
Dividend History
Cassava Sciences Inc stock is traded at $3.155, with a volume of 834.51K.
It is down -3.53% in the last 24 hours and down -13.36% over the past month.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
See More
Previous Close:
$3.26
Open:
$3.3
24h Volume:
834.51K
Relative Volume:
0.34
Market Cap:
$151.93M
Revenue:
-
Net Income/Loss:
$-97.22M
P/E Ratio:
-2.2862
EPS:
-1.38
Net Cash Flow:
$-82.44M
1W Performance:
-17.24%
1M Performance:
-13.36%
6M Performance:
+95.34%
1Y Performance:
-88.00%
1-Day Range:
$3.045
$3.32
1-Week Range:
$3.045
$3.81
52-Week Range:
$1.15
$33.98
Cassava Sciences Inc Stock (SAVA) Company Profile
Name
Cassava Sciences Inc
Sector
Industry
Phone
512-501-2444
Address
6801 N CAPITAL OF TEXAS HIGHWAY, AUSTIN, TX
Compare SAVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SAVA
Cassava Sciences Inc
|
3.145 | 157.48M | 0 | -97.22M | -82.44M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.14 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
643.35 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.69 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.79 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.16 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cassava Sciences Inc Stock (SAVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-08-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-16-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-15-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-27-21 | Initiated | B. Riley Securities | Buy |
| Feb-16-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-23-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-18-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-15-20 | Downgrade | Maxim Group | Buy → Hold |
| Jan-10-20 | Reiterated | Maxim Group | Buy |
View All
Cassava Sciences Inc Stock (SAVA) Latest News
Why Cassava Sciences Inc. (PX91) stock appeals to dividend investorsBuy Signal & Verified Short-Term Plans - newser.com
Why analysts upgrade Cassava Sciences Inc. stockJuly 2025 Sector Moves & Free Safe Capital Growth Stock Tips - newser.com
Can Cassava Sciences Inc. Equity Warrant stock maintain operating marginsBuy Signal & Free Daily Entry Point Trade Alerts - newser.com
How institutional ownership impacts Cassava Sciences Inc. Equity Warrant stockStock Surge & Safe Swing Trade Setup Alerts - newser.com
What risks investors should watch in Cassava Sciences Inc. stock2025 Fundamental Recap & Weekly Momentum Stock Picks - newser.com
What analyst consensus says on Cassava Sciences Inc. stockJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - newser.com
Will Cassava Sciences Inc. Equity Warrant stock benefit from green energy trendsMarket Weekly Review & Weekly Top Stock Performers List - newser.com
Will Cassava Sciences Inc. continue its uptrendEntry Point & Stepwise Trade Signal Implementation - newser.com
Is it too late to sell Cassava Sciences Inc.July 2025 Fed Impact & Community Shared Stock Ideas - newser.com
Cassava Sciences Inc. Equity Warrant stock volume spike explainedEarnings Trend Report & Real-Time Market Sentiment Alerts - newser.com
Will Cassava Sciences Inc. Equity Warrant stock deliver shareholder valueBear Alert & Daily Stock Trend Watchlist - newser.com
How currency fluctuations impact Cassava Sciences Inc. stockJuly 2025 Decliners & Consistent Return Strategy Ideas - newser.com
Is Cassava Sciences Inc. Equity Warrant stock bottoming outJuly 2025 Earnings & Reliable Momentum Entry Alerts - newser.com
Why Cassava Sciences Inc. (PX91) stock could be next leaderLayoff News & Accurate Intraday Trading Signals - newser.com
Why Cassava Sciences Inc. Equity Warrant is moving todayBull Run & Safe Capital Growth Stock Tips - newser.com
Is Cassava Sciences Inc. stock a buy on dipsGDP Growth & Weekly Market Pulse Alerts - newser.com
Risk adjusted return profile for Cassava Sciences Inc. analyzedMarket Trend Summary & Daily Momentum Trading Reports - newser.com
Can Cassava Sciences Inc. stock attract ESG capital inflowsEarnings Beat & Stock Portfolio Risk Control - newser.com
Tools to monitor Cassava Sciences Inc. Equity Warrant recovery probabilityTrade Risk Report & Daily Stock Trend Reports - newser.com
Full technical analysis of Cassava Sciences Inc. stockEarnings Miss & Advanced Technical Signal Analysis - newser.com
Is Cassava Sciences Inc. Equity Warrant stock affected by interest rate hikesAnalyst Downgrade & Stepwise Entry and Exit Trade Signals - newser.com
Will Cassava Sciences Inc. Equity Warrant stock keep outperforming rivalsJuly 2025 EndofMonth & Reliable Volume Spike Trade Alerts - newser.com
Will Cassava Sciences Inc. Equity Warrant stock benefit from sector rotationM&A Rumor & Verified Swing Trading Watchlists - newser.com
Why Cassava Sciences Inc. Equity Warrant stock is a value investor pickM&A Rumor & Stock Portfolio Risk Control - newser.com
Can Cassava Sciences Inc. (PX91) stock ride next bull market cycleSell Signal & Technical Analysis for Trade Confirmation - newser.com
Will Cassava Sciences Inc. stock go up soon2025 Risk Factors & Consistent Growth Equity Picks - newser.com
How strong is Cassava Sciences Inc. stock revenue growth2025 EndofYear Setup & Safe Capital Allocation Plans - newser.com
What analysts say about Maywood Acquisition Corp stockRelative Strength Index (RSI) & Budget Friendly Trading Strategies - earlytimes.in
Why Cassava Sciences Inc. stock is in analyst buy zoneMarket Activity Report & Safe Entry Momentum Tips - newser.com
Chart overlay techniques for tracking Cassava Sciences Inc.July 2025 WrapUp & Low Volatility Stock Suggestions - newser.com
Will Cassava Sciences Inc. (PX91) stock benefit from mergersMarket Sentiment Summary & Proven Capital Preservation Methods - newser.com
Cassava Sciences (NASDAQ:SAVA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
What the charts say about Cassava Sciences Inc. today2025 Trading Volume Trends & Daily Growth Stock Investment Tips - newser.com
Cassava Sciences Inc Stock (SAVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cassava Sciences Inc Stock (SAVA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Barry Richard | President & CEO |
Sep 22 '25 |
Buy |
2.28 |
7,172 |
16,352 |
714,675 |
| Barry Richard | President & CEO |
Sep 18 '25 |
Buy |
2.24 |
190,633 |
426,424 |
660,195 |
| Barry Richard | President & CEO |
Sep 19 '25 |
Buy |
2.29 |
47,308 |
108,319 |
707,503 |
| Kupiec James William | Chief Medical Officer |
Nov 29 '24 |
Sale |
3.87 |
4,000 |
15,480 |
0 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
1.18 |
50,000 |
59,000 |
71,300 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.86 |
59,800 |
230,828 |
11,500 |
| Schoen Eric | Chief Financial Officer |
Nov 29 '24 |
Sale |
3.82 |
2,000 |
7,640 |
0 |
0.29%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):